Osteoporosis medicines fall into two broad groups. Antiresorptive agents slow bone breakdown. Anabolic agents stimulate bone formation. For hospital pharmacies, clinics and procurement teams in India, the difference matters because the two groups differ in course length, storage and how they are sequenced. This article reports what published trials and reviews say, and what supply teams should plan for. It does not recommend any treatment.
Antiresorptive and anabolic therapy: the basic difference
Bisphosphonates and denosumab are antiresorptive. They reduce the rate at which bone is removed. Teriparatide, a recombinant fragment of human parathyroid hormone (PTH 1-34), and romosozumab are anabolic. They are used to build new bone. A published review of anabolic therapy describes these agents as generally reserved for severe osteoporosis at very high fracture risk, with recency of a prior fracture described as the key predictor of imminent risk.
What the key trials reported
The review summarises several pivotal trials, with fracture reductions expressed as relative risk reductions:
| Trial | Comparator | Duration | Vertebral fracture |
|---|---|---|---|
| VERO (teriparatide) | Risedronate | 24 months | 56% reduction |
| ARCH (romosozumab, then alendronic acid) | Alendronic acid | 24 months | 48% reduction |
| FRAME (romosozumab) | Placebo | 12 months | 73% reduction |
| Fracture Prevention Trial (teriparatide 20 µg) | Placebo | 21 months | 65% reduction |
In VERO, the same review reports non-vertebral fracture reduction of 34% and clinical fracture reduction of 52% for teriparatide against risedronate. These are trial results in specific populations, not predictions for an individual patient.
Course length and what follows
Teriparatide use is limited to 24 months over a lifetime because of a theoretical osteosarcoma risk seen in high-dose rodent studies. The review notes that human post-marketing data have not shown this risk, and that persistent hypercalcaemia occurs in about 3% of patients. After an anabolic course, the literature describes following with an antiresorptive to maintain bone density gains, since stopping teriparatide may be followed by relatively rapid bone loss. Repeat teriparatide courses showed an attenuated density response. For supply teams, the practical meaning is a defined course, with continuity of the follow-on medicine to plan alongside it.
Safety information reported for romosozumab
In ARCH, major cardiovascular events were 2.5% with romosozumab against 1.9% with alendronic acid over 12 months, and a meta-analysis reported a 39% increase in four-point MACE. Regulators have restricted its use to selected groups, as noted in the review. The treating physician weighs such information for each patient.
Supply and storage planning for injectable anabolic medicines
Daily injectable pens create specific logistics. For a teriparatide pen such as the Terifrac 20 mcg injection pen, the listing states refrigerated storage at 2°C to 8°C, no freezing, and discarding the pen 28 days after first use. For a 24-month course, hospitals and clinics should consider:
- Cold chain: document receipt, storage and dispatch temperatures against the label.
- Batch and expiry checks: verify batch details and shelf life at receipt.
- Continuity: a long course needs uninterrupted supply. Planning stock with the distributor in advance reduces the risk of gaps.
- Genuine supply: buy from a distributor that can document source and paperwork. See our guide on verifying genuine imported medicines.
- Follow-on medicines: antiresorptives such as denosumab are covered in our post on denosumab 60 mg and 120 mg.
Related product listings include Forteo, Prolia, Denorange and Evenity. Medicines are supplied only against a valid prescription from a registered medical practitioner. For medicines not routinely stocked in India, see our explainer on the Named Patient Program.
Working with a medicine distributor in Delhi
A.K. Pharma is a Medicine Distributor in Delhi supplying imported and specialty medicines to hospitals, clinics and doctors across India. To check availability or plan stock for a long injectable course, contact the team at 011 4172 6999 or on WhatsApp at +91 9810034827.
Frequently asked questions
What is the difference between anabolic and antiresorptive osteoporosis medicines?
Antiresorptive medicines slow the breakdown of bone, while anabolic medicines stimulate new bone formation. Teriparatide, a PTH analogue, is an anabolic agent; bisphosphonates and denosumab are antiresorptive agents.
Which patients do the trials and reviews associate with anabolic-first therapy?
Published reviews describe anabolic agents as generally reserved for severe osteoporosis at very high fracture risk, particularly high vertebral fracture risk or a recent fracture. The treating physician makes the decision for each patient.
How long is teriparatide used according to its labelling?
Teriparatide is limited to 24 months over a lifetime, based on a theoretical osteosarcoma signal seen in high-dose rodent studies. Human post-marketing data have not confirmed this risk, according to the review cited in this article.
What did the VERO trial report?
In VERO, teriparatide was compared with risedronate over 24 months in postmenopausal women with severe osteoporosis. The review cited here reports relative reductions of 56% in vertebral fractures, 34% in non-vertebral fractures and 52% in clinical fractures.
What usually follows an anabolic course?
Standard practice described in the literature is to follow the anabolic course with an antiresorptive to maintain the bone density gained. Which antiresorptive works best is described as unclear.
How should teriparatide pens be stored in a hospital pharmacy?
The product listing states storage at 2°C to 8°C, no freezing, and discarding the pen 28 days after first use. Always follow the current package insert and the manufacturer’s instructions.
Why does cold-chain handling matter for injectable osteoporosis medicines?
Pens that are stored outside the labelled temperature range may lose potency. Receiving, storage and dispatch temperatures should be documented and checked against the label.
Can A.K. Pharma supply imported and branded options?
A.K. Pharma is a Delhi-based distributor of imported and specialty medicines. Supply is only against a valid prescription from a registered medical practitioner. Contact the team for availability.
Is this article medical advice?
No. A.K. Pharma is a distributor, not a healthcare provider. The article reports published information. Treatment decisions rest solely with the treating physician.
Source
Published review of anabolic therapy in osteoporosis: PubMed Central, PMC8170684.
Disclaimer: A.K. Pharma is a medicine distributor, not a healthcare provider. This article reports published trial and guideline information and is not medical advice. Treatment decisions rest solely with the treating physician.
